-+ 0.00%
-+ 0.00%
-+ 0.00%

Neumora Therapeutics posts corporate presentation outlining neuroscience drug development pipeline

PUBT·05/07/2026 11:04:15
Listen to the news
Neumora Therapeutics posts corporate presentation outlining neuroscience drug development pipeline
  • Neumora outlined multiple near-term clinical catalysts across three franchises, with navacaprant Phase 3 KOASTAL-2 and KOASTAL-3 topline data expected in 2H 2026.
  • Pipeline progress targets include NMRA-898 Phase 1 data in 2H 2026, NMRA-511 multiple-ascending-dose data in 2H 2026, NMRA-511 Phase 2 study start in 1Q 2027.
  • Metabolic program NMRA-215 is slated to enter clinic in 1Q 2027.
  • Company projected cash runway into 3Q 2027.
  • NMRA-511 Phase 1b readout highlighted tolerability with low discontinuations due to treatment-emergent adverse events of 2.5%, with efficacy signals in Alzheimer’s disease agitation including Cohen’s d effect size of 0.32-0.34 in NPI-AA ≥4 population at Week 6-8, rising to 0.51-0.64 in prespecified elevated-anxiety subgroup.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.